Adam Tomasi Form 4 ZS Pharma / Adam Tomasi ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Tomasi Adam

(Last) (First) (Middle)

1100 PARK PLACE, SUITE 300

(Street)

SAN MATEO CA 94403

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ZS Pharma, Inc. [ ZSPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
12/17/2015

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/17/2015		D		12,599(1)	D	$90	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (NQ) - 8/1/13	$2.1284	12/17/2015		D			155,983	08/01/2014	07/31/2023	Common Stock	155,983	$0.00	0	D
Employee Stock Option (NQ) - 4/24/14	$10.9242	12/17/2015		D			3,190	04/24/2015	04/23/2024	Common Stock	3,190	$0.00	0	D
Employee Stock Option (ISO) - 4/24/14	$10.9242	12/17/2015		D			17,279	04/24/2015	04/23/2024	Common Stock	17,279	$0.00	0	D
Employee Stock Option (ISO) - 7/8/14	$27.16	12/17/2015		D			4,095	07/07/2015	07/06/2024	Common Stock	4,095	$0.00	0	D
Employee Stock Option (NQ) - 7/8/14	$27.16	12/17/2015		D			22,125	07/07/2015	07/06/2024	Common Stock	22,125	$0.00	0	D
Employee Stock Option (ISO) - 1/23/15	$46	12/17/2015		D			99	01/23/2016	01/22/2025	Common Stock	99	$0.00	0	D
Employee Stock Option (NQ) - 1/23/15	$46	12/17/2015		D			4,675	01/23/2016	01/22/2025	Common Stock	4,675	$0.00	0	D
Employee Stock Option (ISO) - 6/18/15	$55.57	12/17/2015		D			1,717	06/18/2016	06/17/2025	Common Stock	1,717	$0.00	0	D
Employee Stock Option (NQ) - 6/18/15	$55.57	12/17/2015		D			15,158	06/18/2016	06/17/2025	Common Stock	15,158	$0.00	0	D

Explanation of Responses:

1. Includes 3,000 shares in the form of restricted stock units and 443 shares acquired under the Employee Stock Purchase Plan on December 9, 2015

Remarks:

Chief Scientific Officer and Head of Corporate Development

	/s/ Adam Tomasi	12/21/2015
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.